# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-11-2022 | 06-30-2022 | 10-Q | |
2 | 05-12-2022 | 03-31-2022 | 10-Q | |
3 | 03-18-2022 | 12-31-2021 | 10-K | |
4 | 08-13-2021 | 06-30-2021 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On average, software companies beat Q2 revenue estimates by 2% and profitability expectations by 5%, RBC analyst Matthew Hedber...
CL King analyst David Silver maintains Xometry (NASDAQ:XMTR) with a Buy and raises the price target from $55 to $65.
SVB Leerink cut the price target on Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) from $8 to $4. SVB Leerink analyst Daina Grayb...
 Analysts have provided the following ratings for Xometry (NASDAQ:XMTR) within the last quarter:
Goldman Sachs analyst Eric Sheridan maintains Xometry (NASDAQ:XMTR) with a Buy and raises the price target from $44 to $64.
RBC Capital analyst Matthew Hedberg maintains Xometry (NASDAQ:XMTR) with a Outperform and raises the price target from $46 t...
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 ...
Â